reports
- Maxim Jacobs
Multiple shots on goal and multiple partners
BioLineRx is currently focused on the development of BL-8040, which is a short peptide antagonist for CXCR4, a chemokine receptor involved with tumor progression, angiogenesis, metastasis and cell survival. BL-8040 is being developed for a variety of solid tumors including pancreatic, gastric and NSCLC. It is also being developed for AML and stem cell mobilization. They are also developing AGI-134, an alpha-gal immunotherapy for solid tumors, which is expected to enter the clinic within 12 month...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Flash note: BL-8040 progressing in varied cancer types
BioLineRx’s lead compound, BL-8040, is under development in numerous cancer indications, for which we anticipate collective peak sales potential of c $700m. We also expect first launch of its skin lesion product by partner Perrigo in 2016 to yield royalties of c $2-3m per year.
Update: Newsflow-rich period
BioLineRx has provided critical updates on key pipeline projects in recent weeks. It now plans to test a larger cohort at higher doses in its Phase II trial of BL-8040 in acute myeloid leukaemia on the back of encouraging efficacy/safety data presented at the ASH conference this week. Enrolment for the CE mark trial of Bioabsorbable Cardiac Matrix is expected to be completed by year end and study completion is slated for mid-2015. BioLineRx also recently announced positive Phase I/II safety data...
Update: Data and new trials in H214
BioLineRx should report partial data on BL-8040 in acute myeloid leukaemia (AML) and start a new clinical trial with the product in Q314. Upcoming Phase I/II data on BL-7010 for celiac disease should clear the way for its development as a medical device, with a pivotal trial beginning in early 2015. The trial with BL-1040 for patients after an acute myocardial infarction (AMI) has recruited over 200 patients, albeit slower than hoped; completion of this pivotal study is now due in mid-2015.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.